{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:46Z","timestamp":1794018826489,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0108604"],"award-info":[{"award-number":["JP22fk0108604"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23fk0108604"],"award-info":[{"award-number":["JP23fk0108604"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jgar.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T12:36:30Z","timestamp":1716381390000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-3542","authenticated-orcid":false,"given":"Shizuo","family":"Kayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayoko","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6451-2728","authenticated-orcid":false,"given":"Kohei","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-8907","authenticated-orcid":false,"given":"Liansheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-8524","authenticated-orcid":false,"given":"Wataru","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-1115","authenticated-orcid":false,"given":"Koji","family":"Yahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-7739","authenticated-orcid":false,"given":"Motoyuki","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.05.009_bib0001","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.009_bib0002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2024.05.009_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.jgar.2024.05.009_bib0004","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.009_bib0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.009_bib0007","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0009","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR gram-negative infections","volume":"71","author":"Falcone","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02729-16","article-title":"Global molecular epidemiology of IMP-producing Enterobacteriaceae","volume":"61","author":"Matsumura","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0013","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.009_bib0014","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum \u03b2-lactamases and carbapenemases","volume":"63","author":"Jacobs","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0017","first-page":"e02670","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-Network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.05.009_bib0018","doi-asserted-by":"crossref","first-page":"dlaa081","DOI":"10.1093\/jacamr\/dlaa081","article-title":"Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study","volume":"2","author":"Sato","year":"2020","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.009_bib0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7883\/yoken.JJID.2020.499","article-title":"Japan Nosocomial Infections Surveillance (JANIS): current status, international collaboration, and future directions for a comprehensive antimicrobial resistance surveillance system","volume":"74","author":"Kajihara","year":"2021","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1038\/s41467-023-43516-4","article-title":"National genomic surveillance integrating standardized quantitative susceptibility testing clarifies antimicrobial resistance in Enterobacterales","volume":"14","author":"Kayama","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2024.05.009_bib0021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0022","doi-asserted-by":"crossref","first-page":"e01990","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jgar.2021.12.017","article-title":"Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan","volume":"28","author":"Yamano","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.009_bib0024","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime\u2013avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.009_bib0026","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.009_bib0027","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.02398-13","article-title":"Post-\u03b2-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-\u03b2-lactamase-producing strains","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0028","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam: two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections","volume":"46","author":"Liscio","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.009_bib0029","doi-asserted-by":"crossref","first-page":"e00918","DOI":"10.1128\/aac.00918-22","article-title":"In vitro mechanisms of resistance development to imipenem-relebactam in KPC-producing Klebsiella pneumoniae","volume":"66","author":"Findlay","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2024.05.009_bib0031","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime\u2013avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.05.009_bib0032","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/jac\/dkab304","article-title":"No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales","volume":"76","author":"Jacob","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.009_bib0033","doi-asserted-by":"crossref","first-page":"e00311","DOI":"10.1128\/aac.00311-22","article-title":"NDM-35-producing ST167 Escherichia coli highly resistant to \u03b2-lactams including cefiderocol","volume":"66","author":"Poirel","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1016\/j.jgar.2025.08.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:23:35Z","timestamp":1778858615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"alternative-id":["S2213716524000985"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}